AbbVie announced it will present 23 abstracts s at the 31(st) European Academy of Dermatology and Venereology (EADV) Congress, including a late-breaking oral presentation on long-term efficacy and safety data of SKYRIZI(R) (risankizumab) in psoriatic arthritis and real-world data from MEASURE-AD to assess the multidimensional burden of atopic dermatitis. This research demonstrates AbbVie's commitment to deepening the understanding of immune-mediated skin diseases by investing in studies of difficult-to-treat patient populations, certain disease areas with few existing treatment options as well as real-world patient experience. The hybrid congress will take place from September 7-10, in Milan, as well as virtually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167.3 USD | -0.30% | +1.60% | +7.95% |
Apr. 25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
Apr. 25 | AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.95% | 297B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B | |
+2.07% | 117B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology 2022 Congress